Mark E. Dmytruk - Mar 1, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Chief Financial Officer
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/3/2023, 04:30 PM
Previous filing: Feb 3, 2023
Next filing: Mar 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Options Exercise		+1.64K	+0.33%		495K	Mar 1, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Class B Common Stock	Options Exercise		-1.64K	-0.25%		650K	Mar 1, 2023	Class A Common Stock	1.64K		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F2	Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F3	Includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Financial Officer